ResMed Inc. (RMD)

NYSE · San Diego, California, USA · Founded 1989 · CEO Mick Farrell

Valuation summary

$179.91 fair value versus $236.88 in the market, a difference of -24.1%. Rated Reduce.

Fair value per share$179.91
Current share price$236.88
Upside / downside-24.1%
Bear case$120.92
Bull case$264.92
Discount rate (WACC)8.9%
Terminal growth2.80%
Market capitalisation$33B
EV / Sales5.9x

About ResMed Inc.

Founded in 1989 in Australia by Peter Farrell to commercialise a treatment for sleep apnoea invented at the University of Sydney. His son Mick Farrell has been chief executive since 2013. ResMed makes the machines and masks that keep a sleeper's airway open with gentle air pressure, and is the world leader after its main rival Philips was forced to recall its devices. It also sells software used by home-care providers.

Investment case

  • Hundreds of millions of people have untreated sleep apnoea.
  • Masks need regular replacement, which makes revenue recurring.
  • High margins and no net debt.

Key risks

  • Weight-loss drugs reduce sleep apnoea in some patients, which worries investors.
  • Philips is returning to the market outside the United States.
  • Depends on insurance reimbursement rules.

Revenue by segment

Sleep and breathing devices52%
Masks and accessories36%
Residential care software12%

Five-year forecast

RevenueFree cash flow
Year 1$6.1B$1.1B
Year 2$6.7B$1.2B
Year 3$7.3B$1.3B
Year 4$7.9B$1.4B
Year 5$8.7B$1.5B

What the street says

A high-quality medical device company; the debate is how much weight-loss drugs matter.

Comparable companies: A · IDXX · EW · DXCM · ABT · BIIB · SNY · SYK

Open the interactive model, price chart and sensitivity grid →